Korro Bio, Inc.
KRRO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001703647
In the last 90 days, Korro Bio, Inc. insiders filed 1 open-market purchase and 6 sales; 106 institutions reported holding it in 13F filings for Q2 2026, worth $190.1M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:57 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $117.3M (1834.5% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 9, 2026 | Mar 18, 2025 | Mar 26, 2024 | Feb 13, 2023 | Mar 15, 2022 |
| Revenue | $6.39M | $2.27M | – | $0 | $14.1M |
| Operating expenses | $128.2M | $94.2M | $84.5M | $83.0M | $98.1M |
| Research and development | $65.6M | $63.6M | $57.3M | $49.4M | $60.9M |
| Selling, general and administrative | $28.2M | $30.5M | $27.3M | $33.6M | $37.2M |
| Operating income | -$121.9M | -$91.9M | -$84.5M | -$83.0M | -$84.0M |
| Interest expense | – | – | – | $961.0K | $764.0K |
| Income tax | $637.0K | $141.0K | $27.0K | -$2.00K | $15.0K |
| Net income | -$117.3M | -$83.6M | -$81.2M | -$81.6M | -$84.7M |
| EPS, basic | $-12.48 | $-9.37 | $-53.08 | – | – |
| EPS, diluted | $-12.48 | $-9.37 | $-53.08 | – | – |
| Weighted shares, basic | 9.40M | 8.92M | 1.53M | – | – |
| Weighted shares, diluted | 9.40M | 8.92M | 1.53M | – | – |
| Margins and growth | |||||
| Operating margin | -1906.4% | -4047.1% | – | – | -597.3% |
| Net margin | -1834.5% | -3680.4% | – | – | -602.0% |
| Revenue growth, year over year | +181.5% | – | – | −100.0% | −62.0% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 9, 2026 | Mar 18, 2025 | Mar 26, 2024 | Feb 13, 2023 | Mar 15, 2022 |
| Cash and equivalents | $21.8M | $55.6M | $166.2M | $52.0M | $79.6M |
| Short-term investments | $53.3M | $70.5M | $0 | – | – |
| Total current assets | $82.4M | $131.5M | $172.7M | $87.5M | $134.7M |
| Property, plant and equipment | $8.16M | $27.7M | $15.7M | $2.74M | $5.52M |
| Total assets | $113.5M | $226.2M | $221.7M | $121.2M | $185.4M |
| Accounts payable | $1.65M | $3.99M | $7.28M | $3.11M | $2.75M |
| Short-term debt | – | – | – | $10.0M | $833.0K |
| Total current liabilities | $11.9M | $15.0M | $19.5M | $21.0M | $11.4M |
| Total liabilities | $62.1M | $65.8M | $51.8M | $52.0M | $54.5M |
| Shareholders' equity | $51.4M | $160.4M | $169.9M | $69.2M | $130.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 9, 2026 | Mar 18, 2025 | Mar 26, 2024 | Feb 13, 2023 | Mar 15, 2022 |
| Operating cash flow | -$78.6M | -$60.1M | -$67.3M | -$58.2M | -$76.1M |
| Capital expenditures | $518.0K | $17.9M | $7.84M | $0 | $2.91M |
| Free cash flow | -$79.1M | -$78.0M | -$75.1M | -$58.2M | -$79.0M |
| Stock-based compensation | $7.66M | $4.46M | $2.38M | $19.8M | $21.8M |
| Investing cash flow | $44.0M | -$123.3M | $11.2M | $31.1M | -$66.1M |
| Financing cash flow | $685.0K | $69.4M | $187.8M | -$577.0K | $1.36M |
| Net change in cash | -$33.8M | -$114.1M | $131.6M | -$27.7M | -$140.8M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 119.8% | 196.5% | – | – | 154.6% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 3, 2026 | 13.7M | +45.7% | SEC |
| Aug 5, 2026 | 14.7M | +56.8% | SEC |
| May 4, 2026 | 14.4M | +53.6% | SEC |
| Mar 10, 2026 | 14.4M | +53.6% | SEC |
| Nov 10, 2025 | 9.42M | +0.5% | SEC |
| Aug 8, 2025 | 9.39M | +1.0% | SEC |
| May 5, 2025 | 9.39M | +1.3% | SEC |
| Mar 14, 2025 | 9.39M | +17.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.